Peters William J reported option exercise involving 16,000 derivative units of Amphastar Pharmaceuticals, Inc. at $0.00 for $0 on Nov 4, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CFO, EVP & TREASURER
CFO, EVP & TREASURER
Filed Nov 6, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
16,000Employee Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
7,674Direct
Trade date
Nov 4, 2026Option exercise
Filed
Nov 6, 2026, 4:17 PM ET2-day reporting delay
Accession
0001263136-26-000016Code M · Transaction 394783
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 4, 2026Sell16,000$28.03−$448,480Trade 394780
Nov 5, 2026Sell12,631$28.99−$366,189.11Trade 394782
Nov 5, 2026Option exercise11,000$0.00$0Trade 394784
Nov 4, 2026Option exercise16,000$13.03$208,480Trade 394779
Nov 5, 2026Option exercise11,000$17.99$197,890Trade 394781
6 transaction rows in this filing. Joint filers share the same rows.

AMPH price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
AMPH · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −0.8%1w ago 0%1d ago 0%
Returns since7d +15%30d90d180d1y

Footnotes in full

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.99 to $29.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3: Shares subject to the option are fully vested and immediately exercisable.